Masimo (MASI)
(Delayed Data from NSDQ)
$143.49 USD
+3.55 (2.54%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $143.53 +0.04 (0.03%) 6:24 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$143.49 USD
+3.55 (2.54%)
Updated Oct 9, 2024 04:00 PM ET
After-Market: $143.53 +0.04 (0.03%) 6:24 PM ET
2-Buy of 5 2
C Value A Growth C Momentum B VGM
Zacks News
Cerner's CommunityWorks Picked by Reeves County Hospital
by Zacks Equity Research
Cerner (CERN) sees a slew of developments in its EHR platform, market prospects bright.
Cardiovascular Systems Stealth 360 Peripheral OAS Goes Global
by Zacks Equity Research
Following the recent extension of its partnership with OrbusNeich, Cardiovascular Systems' (CSII) Stealth 360 Peripheral OAS is put to first commercial use in Hong Kong.
Insulet Advances on Omnipod Reimbursement Update, Runs Risks
by Zacks Equity Research
Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.
Here's Why You Should Hold on to Align Technology (ALGN) Now
by Zacks Equity Research
Continued strength in Align Technology's (ALGN) Invisalign volumes impresses. Overdependence on Invisalign Technology system is a concern.
Here's Why You Should Invest in Masimo (MASI) Right Now
by Zacks Equity Research
A raised guidance for 2018 and positive developments make Masimo (MASI) a lucrative choice for investors.
ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio
by Zacks Equity Research
ResMed's (RMD) recent product launches will strengthen its position in the high-potential sleep-disordered breathing market.
QIAGEN (QGEN) Partners DiaSorin to Extend QuantFERON Offers
by Zacks Equity Research
Per QIAGEN (QGEN), the latest LIAISON QuantiFERON-TB Plus Test is likely to tackle the growing transformation of global latent TB testing market into the modern blood-based QuantiFERON technology.
Cooper's MiSight Lens Effective in Checking Juvenile Myopia
by Zacks Equity Research
Cooper's (COO) core CVI business gets a boost from MiSight's positive study results.
Here's Why You Should Add Abbott (ABT) to Your Portfolio Now
by Zacks Equity Research
Abbott (ABT) continues to deliver strong and consistent performance in all segments. The company has also been hogging the limelight within Diabetic Care on progress with its FreeStyle Libre.
CVS Health (CVS) PBM Strengthens, Aetna Deal Shows Promise
by Zacks Equity Research
A robust 2019 PBM selling season is a tailwind for CVS Health (CVS). Additionally, the company's milestone acquisition of Aetna might alter the whole healthcare landscape in the United States.
QIAGEN Collaborates With NeuMoDx, Expands NGS Portfolio
by Zacks Equity Research
QIAGEN (QGEN) forges ahead with deals to strengthen the NGS Platform.
DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand
by Zacks Equity Research
DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid.
Omnicell Continues to Pursue Buyouts, Costs on the Rise
by Zacks Equity Research
Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
Cardiovascular Systems Portfolio Strong, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.
Pacific Biosciences (PACB) Up as VGP Picks Flagship Sequel
by Zacks Equity Research
Pacific Biosciences (PACB) sees a slew of developments in its coveted SMRT Sequel platform.
DENTSPLY Launches Azento, Improves Digital Implant Workflow
by Zacks Equity Research
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.
Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.
Allscripts' Sunrise Abstracting Selected by Wyckoff Heights
by Nabaparna Bhattacharya
Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.
Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT
by Zacks Equity Research
Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.
Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio
by Zacks Equity Research
A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.
Stryker (SYK) to Acquire Invuity, Boost Surgical Portfolio
by Zacks Equity Research
Stryker (SYK) on an acquisition spree; latest buyout likely to aid its array of surgical instruments.
Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.
Here's Why You Should Hold On to DaVita (DVA) Stock Now
by Zacks Equity Research
Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.